1
|
Yee Mon KJ, Blander JM. TAP-ing into the cross-presentation secrets of dendritic cells. Curr Opin Immunol 2023; 83:102327. [PMID: 37116384 DOI: 10.1016/j.coi.2023.102327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2022] [Revised: 03/18/2023] [Accepted: 03/22/2023] [Indexed: 04/30/2023]
Abstract
Viral blockade of the transporter associated with antigen processing (TAP) diminishes surface and endosomal recycling compartment levels of major histocompatibility complex class-I (MHC-I) in dendritic cells (DCs), and compromises both classical MHC-I presentation and canonical cross-presentation during infection to impair CD8 T-cell immunity. Virus-specific CD8 T cells are thought to be cross-primed mostly by uninfected TAP-sufficient DCs through cross-presentation of viral peptides from internalized virus-infected dying cells. The dilemma is that CD8 T cells primed to TAP-dependent viral peptides are mismatched to the TAP-independent epitopes presented on tissues infected with immune-evasive viruses. Noncanonical cross-presentation in DCs overcomes cell-intrinsic TAP blockade to nevertheless prime protective TAP-independent CD8 T cells best-matched against the infection. Exploitation of noncanonical cross-presentation may prevent chronic infections with immune-evasive viruses. It may also control immune-evasive cancers that have downmodulated TAP expression.
Collapse
Affiliation(s)
- Kristel Joy Yee Mon
- The Jill Roberts Institute for Research in Inflammatory Bowel Disease, New York, NY, USA; Joan and Sanford I. Weill Department of Medicine, New York, NY, USA
| | - J Magarian Blander
- The Jill Roberts Institute for Research in Inflammatory Bowel Disease, New York, NY, USA; Joan and Sanford I. Weill Department of Medicine, New York, NY, USA; Department of Microbiology and Immunology, New York, NY, USA; Sandra and Edward Meyer Cancer Center, New York, NY, USA; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, Cornell University, New York, NY, USA.
| |
Collapse
|
2
|
Geiger KM, Manoharan M, Coombs R, Arana K, Park CS, Lee AY, Shastri N, Robey EA, Coscoy L. Murine cytomegalovirus downregulates ERAAP and induces an unconventional T cell response to self. Cell Rep 2023; 42:112317. [PMID: 36995940 PMCID: PMC10539480 DOI: 10.1016/j.celrep.2023.112317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 01/02/2023] [Accepted: 03/14/2023] [Indexed: 03/30/2023] Open
Abstract
The endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP) plays a crucial role in shaping the peptide-major histocompatibility complex (MHC) class I repertoire and maintaining immune surveillance. While murine cytomegalovirus (MCMV) has multiple strategies for manipulating the antigen processing pathway to evade immune responses, the host has also developed ways to counter viral immune evasion. In this study, we find that MCMV modulates ERAAP and induces an interferon γ (IFN-γ)-producing CD8+ T cell effector response that targets uninfected ERAAP-deficient cells. We observe that ERAAP downregulation during infection leads to the presentation of the self-peptide FL9 on non-classical Qa-1b, thereby eliciting Qa-1b-restricted QFL T cells to proliferate in the liver and spleen of infected mice. QFL T cells upregulate effector markers upon MCMV infection and are sufficient to reduce viral load after transfer to immunodeficient mice. Our study highlights the consequences of ERAAP dysfunction during viral infection and provides potential targets for anti-viral therapies.
Collapse
Affiliation(s)
- Kristina M Geiger
- Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA 94720, USA; Division of Immunology and Pathogenesis, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA
| | - Michael Manoharan
- Division of Immunology and Pathogenesis, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA
| | - Rachel Coombs
- Division of Immunology and Pathogenesis, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA
| | - Kathya Arana
- Division of Immunology and Pathogenesis, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA
| | - Chan-Su Park
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Angus Y Lee
- Cancer Research Lab, University of California, Berkeley, Berkeley, CA 94720, USA
| | - Nilabh Shastri
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Ellen A Robey
- Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA 94720, USA; Division of Immunology and Pathogenesis, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.
| | - Laurent Coscoy
- Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA 94720, USA; Division of Immunology and Pathogenesis, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.
| |
Collapse
|
3
|
Blander JM. Different routes of MHC-I delivery to phagosomes and their consequences to CD8 T cell immunity. Semin Immunol 2023; 66:101713. [PMID: 36706521 PMCID: PMC10023361 DOI: 10.1016/j.smim.2023.101713] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Revised: 01/08/2023] [Accepted: 01/09/2023] [Indexed: 01/27/2023]
Abstract
Dendritic cells (DCs) present internalized antigens to CD8 T cells through cross-presentation by major histocompatibility complex class I (MHC-I) molecules. While conventional cDC1 excel at cross-presentation, cDC2 can be licensed to cross-present during infection by signals from inflammatory receptors, most prominently Toll-like receptors (TLRs). At the core of the regulation of cross-presentation by TLRs is the control of subcellular MHC-I traffic. Within DCs, MHC-I are enriched within endosomal recycling compartments (ERC) and traffic to microbe-carrying phagosomes under the control of phagosome-compartmentalized TLR signals to favor CD8 T cell cross-priming to microbial antigens. Viral blockade of the transporter associated with antigen processing (TAP), known to inhibit the classic MHC-I presentation of cytoplasmic protein-derived peptides, depletes the ERC stores of MHC-I to simultaneously also block TLR-regulated cross-presentation. DCs counter this impairment in the two major pathways of MHC-I presentation to CD8 T cells by mobilizing noncanonical cross-presentation, which delivers MHC-I to phagosomes from a new location in the ER-Golgi intermediate compartment (ERGIC) where MHC-I abnormally accumulate upon TAP blockade. Noncanonical cross-presentation thus rescues MHC-I presentation and cross-primes TAP-independent CD8 T cells best-matched against target cells infected with immune evasive viruses. Because noncanonical cross-presentation relies on a phagosome delivery route of MHC-I that is not under TLR control, it risks potential cross-presentation of self-antigens during infection. Here I review these findings to illustrate how the subcellular route of MHC-I to phagosomes critically impacts the regulation of cross-presentation and the nature of the CD8 T cell response to infection and cancer. I highlight important and novel implications to CD8 T cell vaccines and immunotherapy.
Collapse
Affiliation(s)
- J Magarian Blander
- The Jill Roberts Institute for Research in Inflammatory Bowel Disease, USA; Joan and Sanford I. Weill Department of Medicine, USA; Department of Microbiology and Immunology, USA; Sandra and Edward Meyer Cancer Center, USA; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, Cornell University, New York, NY, USA.
| |
Collapse
|
4
|
Fang X, Guo Z, Liang J, Wen J, Liu Y, Guan X, Li H. Neoantigens and their potential applications in tumor immunotherapy. Oncol Lett 2022; 23:88. [PMID: 35126730 PMCID: PMC8805178 DOI: 10.3892/ol.2022.13208] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Accepted: 01/04/2022] [Indexed: 12/23/2022] Open
Abstract
The incidence of malignant tumors is increasing, the majority of which are associated with high morbidity and mortality rates worldwide. The traditional treatment method for malignant tumors is surgery, coupled with radiotherapy or chemotherapy. However, these therapeutic strategies are frequently accompanied with adverse side effects. Over recent decades, tumor immunotherapy shown promise in demonstrating notable efficacy for the treatment of cancer. With the development of sequencing technology and bioinformatics algorithms, neoantigens have become compelling targets for cancer immunotherapy due to high levels of immunogenicity. In addition, neoantigen-based vaccines have demonstrated potential for cancer therapy, primarily by augmenting T-cell responses. Neoantigens have also been shown to be effective in immune checkpoint blockade therapy. Therefore, neoantigens may serve to be predictive biomarkers and synergistic treatment targets in cancer immunotherapy. The aim of the present review was to provide an overview of the recent progress in the classification, screening and clinical application of neoantigens for cancer therapy.
Collapse
Affiliation(s)
- Xianzhu Fang
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Weifang Medical University, Weifang, Shandong 261053, P.R. China
| | - Zhiliang Guo
- Department of Orthopedic, The 80th Group Army Hospital of Chinese People's Liberation Army, Weifang, Shandong 261021, P.R. China
| | - Jinqing Liang
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Weifang Medical University, Weifang, Shandong 261053, P.R. China
| | - Jiao Wen
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Weifang Medical University, Weifang, Shandong 261053, P.R. China
| | - Yuanyuan Liu
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Weifang Medical University, Weifang, Shandong 261053, P.R. China
| | - Xiumei Guan
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Weifang Medical University, Weifang, Shandong 261053, P.R. China
| | - Hong Li
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Weifang Medical University, Weifang, Shandong 261053, P.R. China
| |
Collapse
|
5
|
Saulle I, Marventano I, Saresella M, Vanetti C, Garziano M, Fenizia C, Trabattoni D, Clerici M, Biasin M. ERAPs Reduce In Vitro HIV Infection by Activating Innate Immune Response. THE JOURNAL OF IMMUNOLOGY 2021; 206:1609-1617. [PMID: 33619214 DOI: 10.4049/jimmunol.2000991] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/28/2020] [Accepted: 01/14/2021] [Indexed: 11/19/2022]
Abstract
Recombinant human (rh) ERAP2-treated PBMCs are less susceptible to in vitro HIV-1 infection even when CD8+ T cells are depleted. We therefore investigated whether ERAP2 can trigger other immunocompetent cells, boosting their antiviral potential. To this end, human monocyte-derived macrophages (MDMs) differentiated from PBMCs of 15 healthy donors were in vitro HIV-1 infected in the presence/absence of 100 ng/ml of rhERAP2, rhERAP1, or rhERAP1+rhERAP2. Notably, rhERAP2 treatment resulted in a 7-fold reduction of HIV-1 replication in MDMs (p < 0.05). This antiviral activity was associated with an increased mRNA expression of CD80, IL-1β, IL-18, and TNF-α (p < 0.01 for cytokine) in in vitro ERAP2-treated HIV-1-infected MDMs and a greater release of IL-1β, TNF-α, IL-6, and IL-8 (p < 0.01 for each cytokine). The rhERAPs addition also induced the functional inflammasome activation by ASC speck formation in monocytes (p < 0.01) and in THP1-derived macrophages (p < 0.01) as well as a rise in the percentage of activated classical (CD14+CD16-HLA-DRII+CCR7+) and intermediate (CD14++CD16+HLA-DRII+CCR7+) monocytes (p < 0.02). Finally, THP-1-derived macrophages showed an increased phagocytosis following all ERAPs treatments. The discovery that ERAPs are able to trigger several antiviral mechanisms in monocyte/macrophages suggests that their anti-HIV potential is not limited to their canonical role in Ag presentation and CD8+ T cell activation. These findings pose the premise to further investigate the role of ERAPs in both innate and adaptive immunostimulatory pathways and suggest their potential use in novel preventive and therapeutic approaches against HIV-1 infection.
Collapse
Affiliation(s)
- Irma Saulle
- Department of Biomedical and Clinical Sciences "L. Sacco," University of Milan, 20157 Milan, Italy.,Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy; and
| | | | | | - Claudia Vanetti
- Department of Biomedical and Clinical Sciences "L. Sacco," University of Milan, 20157 Milan, Italy.,Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy; and
| | - Micaela Garziano
- Department of Biomedical and Clinical Sciences "L. Sacco," University of Milan, 20157 Milan, Italy
| | - Claudio Fenizia
- Department of Biomedical and Clinical Sciences "L. Sacco," University of Milan, 20157 Milan, Italy.,Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy; and
| | - Daria Trabattoni
- Department of Biomedical and Clinical Sciences "L. Sacco," University of Milan, 20157 Milan, Italy
| | - Mario Clerici
- Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy; and.,Fondazione IRCCS Don Carlo Gnocchi ONLUS, 20148 Milan, Italy
| | - Mara Biasin
- Department of Biomedical and Clinical Sciences "L. Sacco," University of Milan, 20157 Milan, Italy;
| |
Collapse
|
6
|
Garrido G, Schrand B, Levay A, Rabasa A, Ferrantella A, Da Silva DM, D'Eramo F, Marijt KA, Zhang Z, Kwon D, Kortylewski M, Kast WM, Dudeja V, van Hall T, Gilboa E. Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors. Cancer Immunol Res 2020; 8:856-868. [PMID: 32295785 DOI: 10.1158/2326-6066.cir-20-0020] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2020] [Revised: 02/25/2020] [Accepted: 04/08/2020] [Indexed: 12/21/2022]
Abstract
Vaccination of patients against neoantigens expressed in concurrent tumors, recurrent tumors, or tumors developing in individuals at risk of cancer is posing major challenges in terms of which antigens to target and is limited to patients expressing neoantigens in their tumors. Here, we describe a vaccination strategy against antigens that were induced in tumor cells by downregulation of the peptide transporter associated with antigen processing (TAP). Vaccination against TAP downregulation-induced antigens was more effective than vaccination against mutation-derived neoantigens, was devoid of measurable toxicity, and inhibited the growth of concurrent and future tumors in models of recurrence and premalignant disease. Human CD8+ T cells stimulated with TAPlow dendritic cells elicited a polyclonal T-cell response that recognized tumor cells with experimentally reduced TAP expression. Vaccination against TAP downregulation-induced antigens overcomes the main limitations of vaccinating against mostly unique tumor-resident neoantigens and could represent a simpler vaccination strategy that will be applicable to most patients with cancer.
Collapse
Affiliation(s)
- Greta Garrido
- Department of Microbiology and Immunology, University of Miami, Miller School of Medicine, Miami, Florida
| | - Brett Schrand
- Department of Microbiology and Immunology, University of Miami, Miller School of Medicine, Miami, Florida
| | - Agata Levay
- Department of Microbiology and Immunology, University of Miami, Miller School of Medicine, Miami, Florida
| | - Ailem Rabasa
- Department of Microbiology and Immunology, University of Miami, Miller School of Medicine, Miami, Florida
| | - Anthony Ferrantella
- Department of Surgery, University of Miami, Miller School of Medicine, Miami, Florida
| | - Diane M Da Silva
- Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California
| | - Francesca D'Eramo
- Department of Microbiology and Immunology, University of Miami, Miller School of Medicine, Miami, Florida
| | - Koen A Marijt
- Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands
| | - Zhuoran Zhang
- Department of Immuno-Oncology, Beckman Research Institute, City of Hope Medical Center, Duarte, California
| | - Deukwoo Kwon
- Department of Public Health Sciences, University of Miami, Miller School of Medicine, Miami, Florida
| | - Marcin Kortylewski
- Department of Immuno-Oncology, Beckman Research Institute, City of Hope Medical Center, Duarte, California
| | - W Martin Kast
- Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California
| | - Vikas Dudeja
- Department of Surgery, University of Miami, Miller School of Medicine, Miami, Florida.,Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida
| | - Thorbald van Hall
- Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands
| | - Eli Gilboa
- Department of Microbiology and Immunology, University of Miami, Miller School of Medicine, Miami, Florida. .,Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, Florida
| |
Collapse
|
7
|
Garrido G, Schrand B, Rabasa A, Levay A, D'Eramo F, Berezhnoy A, Modi S, Gefen T, Marijt K, Doorduijn E, Dudeja V, van Hall T, Gilboa E. Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity. Nat Commun 2019; 10:3773. [PMID: 31434881 PMCID: PMC6704146 DOI: 10.1038/s41467-019-11728-2] [Citation(s) in RCA: 45] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2018] [Accepted: 08/01/2019] [Indexed: 12/21/2022] Open
Abstract
Neoantigen burden is a major determinant of tumor immunogenicity, underscored by recent clinical experience with checkpoint blockade therapy. Yet the majority of patients do not express, or express too few, neoantigens, and hence are less responsive to immune therapy. Here we describe an approach whereby a common set of new antigens are induced in tumor cells in situ by transient downregulation of the transporter associated with antigen processing (TAP). Administration of TAP siRNA conjugated to a broad-range tumor-targeting nucleolin aptamer inhibited tumor growth in multiple tumor models without measurable toxicity, was comparatively effective to vaccination against prototypic mutation-generated neoantigens, potentiated the antitumor effect of PD-1 antibody or Flt3 ligand, and induced the presentation of a TAP-independent peptide in human tumor cells. Treatment with the chemically-synthesized nucleolin aptamer-TAP siRNA conjugate represents a broadly-applicable approach to increase the antigenicity of tumor lesions and thereby enhance the effectiveness of immune potentiating therapies.
Collapse
Affiliation(s)
- Greta Garrido
- Department of Microbiology and Immunology, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Brett Schrand
- Department of Microbiology and Immunology, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Ailem Rabasa
- Department of Microbiology and Immunology, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Agata Levay
- Department of Microbiology and Immunology, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Francesca D'Eramo
- Department of Microbiology and Immunology, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Alexey Berezhnoy
- Department of Microbiology and Immunology, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Shrey Modi
- Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Tal Gefen
- Department of Microbiology and Immunology, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Koen Marijt
- Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands
| | - Elien Doorduijn
- Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands
| | - Vikas Dudeja
- Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - Thorbald van Hall
- Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands
| | - Eli Gilboa
- Department of Microbiology and Immunology, University of Miami, Miller School of Medicine, Miami, FL, USA.
| |
Collapse
|
8
|
Kanaseki T, Tokita S, Torigoe T. Proteogenomic discovery of cancer antigens: Neoantigens and beyond. Pathol Int 2019; 69:511-518. [PMID: 31397525 DOI: 10.1111/pin.12841] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Accepted: 07/07/2019] [Indexed: 12/24/2022]
Abstract
Host T cells infiltrate the cancer lesion and contribute to patient survival. T cells recognize antigen peptides displayed by the cancer cell human leukocyte antigen (HLA) system. Cancer antigens constitute an essential element of T-cell discrimination and play an indispensable role in anti-cancer responses. HLA ligandome analysis directly and comprehensively detects the peptides that are naturally presented by HLA of given cells, leading to discovery of cancer antigens. A proteogenomic approach, which combines conventional proteomics with genomic information, has further deciphered the landscape of the cancer HLA ligandome. Neoantigens that arise from somatic mutations are arguably the major type of peptides patient T cells recognize. Moreover, cancer cells present peptides derived from alleged noncoding regions, which also elicit T-cell responses thereby serving as cancer antigens. The diversity of newly discovered antigen sources implies that T cells are capable of sensing a variety of genomic aberrations in cancer.
Collapse
Affiliation(s)
| | - Serina Tokita
- Department of Pathology, Sapporo Medical University, Sapporo, Japan.,Sapporo Dohto Hospital, Sapporo, Japan
| | | |
Collapse
|
9
|
Huaman J, Naidoo M, Zang X, Ogunwobi OO. Fibronectin Regulation of Integrin B1 and SLUG in Circulating Tumor Cells. Cells 2019; 8:cells8060618. [PMID: 31226820 PMCID: PMC6627780 DOI: 10.3390/cells8060618] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Revised: 06/18/2019] [Accepted: 06/19/2019] [Indexed: 12/12/2022] Open
Abstract
Metastasis is the leading cause of cancer death worldwide. Circulating tumor cells (CTCs) are a critical step in the metastatic cascade and a good tool to study this process. We isolated CTCs from a syngeneic mouse model of hepatocellular carcinoma (HCC) and a human xenograft mouse model of castration-resistant prostate cancer (CRPC). From these models, novel primary tumor and CTC cell lines were established. CTCs exhibited greater migration than primary tumor-derived cells, as well as epithelial-to-mesenchymal transition (EMT), as observed from decreased E-cadherin and increased SLUG and fibronectin expression. Additionally, when fibronectin was knocked down in CTCs, integrin B1 and SLUG were decreased, indicating regulation of these molecules by fibronectin. Investigation of cell surface molecules and secreted cytokines conferring immunomodulatory advantage to CTCs revealed decreased major histocompatibility complex class I (MHCI) expression and decreased endostatin, C-X-C motif chemokine 5 (CXCL5), and proliferin secretion by CTCs. Taken together, these findings indicate that CTCs exhibit distinct characteristics from primary tumor-derived cells. Furthermore, CTCs demonstrate enhanced migration in part through fibronectin regulation of integrin B1 and SLUG. Further study of CTC biology will likely uncover additional important mechanisms of cancer metastasis.
Collapse
Affiliation(s)
- Jeannette Huaman
- Department of Biological Sciences, Hunter College of The City University of New York, New York, NY 10065, USA.
- Department of Biology, The Graduate Center of The City University of New York, New York, NY 10016, USA.
| | - Michelle Naidoo
- Department of Biological Sciences, Hunter College of The City University of New York, New York, NY 10065, USA.
- Department of Biology, The Graduate Center of The City University of New York, New York, NY 10016, USA.
| | - Xingxing Zang
- Departments of Microbiology and Immunology, and Medicine (Oncology), Albert Einstein College of Medicine, Bronx, NY 10461, USA.
| | - Olorunseun O Ogunwobi
- Department of Biological Sciences, Hunter College of The City University of New York, New York, NY 10065, USA.
- Department of Biology, The Graduate Center of The City University of New York, New York, NY 10016, USA.
- Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY 10065, USA.
| |
Collapse
|
10
|
ERAP1 shapes just part of the immunopeptidome. Hum Immunol 2019; 80:296-301. [DOI: 10.1016/j.humimm.2019.03.004] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2019] [Revised: 03/04/2019] [Accepted: 03/04/2019] [Indexed: 01/22/2023]
|
11
|
Hongo A, Kanaseki T, Tokita S, Kochin V, Miyamoto S, Hashino Y, Codd A, Kawai N, Nakatsugawa M, Hirohashi Y, Sato N, Torigoe T. Upstream Position of Proline Defines Peptide-HLA Class I Repertoire Formation and CD8 + T Cell Responses. THE JOURNAL OF IMMUNOLOGY 2019; 202:2849-2855. [PMID: 30936292 DOI: 10.4049/jimmunol.1900029] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/08/2019] [Accepted: 03/08/2019] [Indexed: 02/02/2023]
Abstract
Cytotoxic CD8+ T lymphocytes (CTLs) recognize peptides displayed by HLA class I molecules on cell surfaces, monitoring pathological conditions such as cancer. Difficulty in predicting HLA class I ligands is attributed to the complexity of the Ag processing pathway across the cytosol and the endoplasmic reticulum. By means of HLA ligandome analysis using mass spectrometry, we collected natural HLA class I ligands on a large scale and analyzed the source-protein sequences flanking the ligands. This comprehensive analysis revealed that the frequency of proline at amino acid positions 1-3 upstream of the ligands was selectively decreased. The depleted proline signature was the strongest among all the upstream and downstream profiles. Experiments using live cells demonstrated that the presence of proline at upstream positions 1-3 attenuated CTL responses against a model epitope. Other experiments, in which N-terminal-flanking Ag precursors were confined in the endoplasmic reticulum, demonstrated an inability to remove upstream prolines regardless of their positions, suggesting a need for synergistic action across cellular compartments for making the proline signature. Our results highlight, to our knowledge, a unique role and position of proline for inhibiting downstream epitope presentation, which provides a rule for defining natural peptide-HLA class I repertoire formation and CTL responses.
Collapse
Affiliation(s)
- Ayumi Hongo
- Department of Pathology, Sapporo Medical University, Sapporo, Hokkaido 060-8556, Japan
| | - Takayuki Kanaseki
- Department of Pathology, Sapporo Medical University, Sapporo, Hokkaido 060-8556, Japan;
| | - Serina Tokita
- Department of Pathology, Sapporo Medical University, Sapporo, Hokkaido 060-8556, Japan
| | - Vitaly Kochin
- Department of Immunology, Nagoya University, Nagoya 466-8550, Japan
| | - Sho Miyamoto
- Department of Oral Surgery, Sapporo Medical University, Sapporo, Hokkaido 060-8556, Japan; and
| | - Yuiko Hashino
- Department of Pathology, Sapporo Medical University, Sapporo, Hokkaido 060-8556, Japan
| | - Amy Codd
- Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff CF14 4XN, Wales, United Kingdom
| | - Noriko Kawai
- Department of Pathology, Sapporo Medical University, Sapporo, Hokkaido 060-8556, Japan
| | - Munehide Nakatsugawa
- Department of Pathology, Sapporo Medical University, Sapporo, Hokkaido 060-8556, Japan
| | - Yoshihiko Hirohashi
- Department of Pathology, Sapporo Medical University, Sapporo, Hokkaido 060-8556, Japan
| | - Noriyuki Sato
- Department of Pathology, Sapporo Medical University, Sapporo, Hokkaido 060-8556, Japan
| | - Toshihiko Torigoe
- Department of Pathology, Sapporo Medical University, Sapporo, Hokkaido 060-8556, Japan
| |
Collapse
|
12
|
Sant AJ. Overview of T-Cell Recognition. Clin Immunol 2019. [DOI: 10.1016/b978-0-7020-6896-6.00006-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
13
|
Mo MS, Li GH, Sun CC, Huang SX, Wei L, Zhang LM, Zhou MM, Wu ZH, Guo WY, Yang XL, Chen CJ, Qu SG, He JX, Xu PY. Dopaminergic neurons show increased low-molecular-mass protein 7 activity induced by 6-hydroxydopamine in vitro and in vivo. Transl Neurodegener 2018; 7:19. [PMID: 30128145 PMCID: PMC6097308 DOI: 10.1186/s40035-018-0125-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2018] [Accepted: 07/30/2018] [Indexed: 02/08/2023] Open
Abstract
Background Abnormal expression of major histocompatibility complex class I (MHC-I) is increased in dopaminergic (DA) neurons in the substantia nigra (SN) in Parkinson’s disease (PD). Low-molecular-mass protein 7 (β5i) is a proteolytic subunit of the immunoproteasome that regulates protein degradation and the MHC pathway in immune cells. Methods In this study, we investigated the role of β5i in DA neurons using a 6-hydroxydopamine (6-OHDA) model in vitro and vivo. Results We showed that 6-OHDA upregulated β5i expression in DA neurons in a concentration- and time-dependent manner. Inhibition and downregulation of β5i induced the expression of glucose-regulated protein (Bip) and exacerbated 6-OHDA neurotoxicity in DA neurons. The inhibition of β5i further promoted the activation of Caspase 3-related pathways induced by 6-OHDA. β5i also activated transporter associated with antigen processing 1 (TAP1) and promoted MHC-I expression on DA neurons. Conclusion Taken together, our data suggest that β5i is activated in DA neurons under 6-OHDA treatment and may play a neuroprotective role in PD. Electronic supplementary material The online version of this article (10.1186/s40035-018-0125-9) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Ming-Shu Mo
- 1Department of Neurology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120 Guangdong China
| | - Gui-Hua Li
- 1Department of Neurology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120 Guangdong China
| | - Cong-Cong Sun
- 2Department of Neurology, Qilu Hospital of Shandong University, Jinan, 250012 Shandong China
| | - Shu-Xuan Huang
- 1Department of Neurology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120 Guangdong China
| | - Lei Wei
- 1Department of Neurology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120 Guangdong China
| | - Li-Min Zhang
- 3Department of Neurology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080 Guangdong China
| | - Miao-Miao Zhou
- 1Department of Neurology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120 Guangdong China
| | - Zhuo-Hua Wu
- 1Department of Neurology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120 Guangdong China
| | - Wen-Yuan Guo
- 1Department of Neurology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120 Guangdong China
| | - Xin-Ling Yang
- 4Department of Neurology, Second Affiliated Hospital of Xinjiang Medical University, Urumchi, 830011 Xinjiang China
| | - Chao-Jun Chen
- Clinic Brain Center, Guangzhou Hospital of Integrated Traditional and Western Medicine, Guangzhou, 510800 Guangdong China
| | - Shao-Gang Qu
- 6Department of Blood Transfusion, Fifth Affiliated Hospital Southern Medical University, Guangzhou, 510900 Guangdong China
| | - Jian-Xing He
- 7Department of Thoracic Surgery, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120 Guangdong China
| | - Ping-Yi Xu
- 1Department of Neurology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120 Guangdong China.,4Department of Neurology, Second Affiliated Hospital of Xinjiang Medical University, Urumchi, 830011 Xinjiang China
| |
Collapse
|
14
|
Shionoya Y, Kanaseki T, Miyamoto S, Tokita S, Hongo A, Kikuchi Y, Kochin V, Watanabe K, Horibe R, Saijo H, Tsukahara T, Hirohashi Y, Takahashi H, Sato N, Torigoe T. Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition. Oncoimmunology 2017; 6:e1274476. [PMID: 28344889 DOI: 10.1080/2162402x.2016.1274476] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2016] [Revised: 11/30/2016] [Accepted: 12/15/2016] [Indexed: 01/05/2023] Open
Abstract
Cytotoxic T-lymphocytes (CTLs) lyse target cells after recognizing the complexes of peptides and MHC class I molecules (pMHC I) on cell surfaces. Tapasin is an essential component of the peptide-loading complex (PLC) and its absence influences the surface repertoire of MHC class I peptides. In the present study, we assessed tapasin expression in 85 primary tumor lesions of non-small cell lung cancer (NSCLC) patients, demonstrating that tapasin expression positively correlated with patient survival. CD8+ T-cell infiltration of tumor lesions was synergistically observed with tapasin expression and correlated positively with survival. To establish a direct link between loss of tapasin and CTL recognition in human cancer models, we targeted the tapasin gene by CRISPR/Cas9 system and generated tapasin-deficient variants of human lung as well as colon cancer cells. We induced the CTLs recognizing endogenous tumor-associated antigens (TAA), survivin or cep55, and they responded to each tapasin-proficient wild type. In contrast, both CTL lines ignored the tapasin-deficient variants despite their antigen expression. Moreover, the adoptive transfer of the cep55-specific CTL line failed to prevent tumor growth in mice bearing the tapasin-deficient variant. Loss of tapasin most likely limited antigen processing of TAAs and led to escape from TAA-specific CTL recognition. Tapasin expression is thus a key for CTL surveillance against human cancers.
Collapse
Affiliation(s)
- Yosuke Shionoya
- Department of Pathology, Sapporo Medical University, Sapporo, Japan; Department of Respiratory Medicine and Allergology, Sapporo Medical University, Sapporo, Japan
| | - Takayuki Kanaseki
- Department of Pathology, Sapporo Medical University , Sapporo, Japan
| | - Sho Miyamoto
- Department of Pathology, Sapporo Medical University , Sapporo, Japan
| | - Serina Tokita
- Department of Pathology, Sapporo Medical University , Sapporo, Japan
| | - Ayumi Hongo
- Department of Pathology, Sapporo Medical University , Sapporo, Japan
| | - Yasuhiro Kikuchi
- Department of Pathology, Sapporo Medical University , Sapporo, Japan
| | - Vitaly Kochin
- Department of Pathology, Sapporo Medical University , Sapporo, Japan
| | - Kazue Watanabe
- Department of Pathology, Sapporo Medical University, Sapporo, Japan; Research and Development Division, Medical and Biological Laboratories Company, Limited, Ina, Japan
| | - Ryota Horibe
- Department of Pathology, Sapporo Medical University, Sapporo, Japan; Department of Respiratory Medicine and Allergology, Sapporo Medical University, Sapporo, Japan
| | - Hiroshi Saijo
- Department of Pathology, Sapporo Medical University, Sapporo, Japan; Department of Respiratory Medicine and Allergology, Sapporo Medical University, Sapporo, Japan
| | | | | | - Hiroki Takahashi
- Department of Respiratory Medicine and Allergology, Sapporo Medical University , Sapporo, Japan
| | - Noriyuki Sato
- Department of Pathology, Sapporo Medical University , Sapporo, Japan
| | - Toshihiko Torigoe
- Department of Pathology, Sapporo Medical University , Sapporo, Japan
| |
Collapse
|
15
|
Schuren AB, Costa AI, Wiertz EJ. Recent advances in viral evasion of the MHC Class I processing pathway. Curr Opin Immunol 2016; 40:43-50. [PMID: 27065088 DOI: 10.1016/j.coi.2016.02.007] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2016] [Revised: 02/12/2016] [Accepted: 02/22/2016] [Indexed: 11/17/2022]
Abstract
T-cell mediated adaptive immunity against viruses relies on recognition of virus-derived peptides by CD4(+) and CD8(+) T cells. Detection of pathogen-derived peptide-MHC-I complexes triggers CD8(+) T cells to eliminate the infected cells. Viruses have evolved several mechanisms to avoid recognition, many of which target the MHC-I antigen-processing pathway. While many immune evasion strategies have been described in the context of herpesvirus infections, it is becoming clear that this 'disguise' ability is more widespread. Here, we address recent findings in viral evasion of the MHC-I antigen presentation pathway and the impact on CD8(+) T cell responses.
Collapse
Affiliation(s)
- Anouk Bc Schuren
- Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Ana I Costa
- Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Emmanuel Jhj Wiertz
- Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands.
| |
Collapse
|
16
|
Sasaki T, Kanaseki T, Shionoya Y, Tokita S, Miyamoto S, Saka E, Kochin V, Takasawa A, Hirohashi Y, Tamura Y, Miyazaki A, Torigoe T, Hiratsuka H, Sato N. Microenvironmental stresses induce HLA-E/Qa-1 surface expression and thereby reduce CD8(+) T-cell recognition of stressed cells. Eur J Immunol 2016; 46:929-40. [PMID: 26711740 DOI: 10.1002/eji.201545835] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2015] [Revised: 11/29/2015] [Accepted: 12/23/2015] [Indexed: 02/04/2023]
Abstract
Hypoxia and glucose deprivation are often observed in the microenvironment surrounding solid tumors in vivo. However, how they interfere with MHC class I antigen processing and CD8(+) T-cell responses remains unclear. In this study, we analyzed the production of antigenic peptides presented by classical MHC class I in mice, and showed that it is quantitatively decreased in the cells exposed to either hypoxia or glucose deprivation. In addition, we unexpectedly found increased surface expression of HLA-E in human and Qa-1 in mouse tumor cells exposed to combined oxygen and glucose deprivation. The induced Qa-1 on the stressed tumor model interacted with an inhibitory NKG2/CD94 receptor on activated CD8(+) T cells and attenuated their specific response to the antigen. Our results thus suggest that microenvironmental stresses modulate not only classical but also nonclassical MHC class I presentation, and confer the stressed cells the capability to escape from the CD8(+) T-cell recognition.
Collapse
Affiliation(s)
- Takanori Sasaki
- Department of Pathology, Sapporo Medical University, Sapporo, Japan
- Department of Oral Surgery, Sapporo Medical University, Sapporo, Japan
| | | | - Yosuke Shionoya
- Department of Pathology, Sapporo Medical University, Sapporo, Japan
- Department of Respiratory Medicine and Allergology, Sapporo Medical University, Sapporo, Japan
| | - Serina Tokita
- Department of Pathology, Sapporo Medical University, Sapporo, Japan
| | - Sho Miyamoto
- Department of Pathology, Sapporo Medical University, Sapporo, Japan
- Department of Oral Surgery, Sapporo Medical University, Sapporo, Japan
| | - Eri Saka
- Department of Pathology, Sapporo Medical University, Sapporo, Japan
| | - Vitaly Kochin
- Department of Pathology, Sapporo Medical University, Sapporo, Japan
| | - Akira Takasawa
- Department of Pathology, Sapporo Medical University, Sapporo, Japan
| | | | - Yasuaki Tamura
- Department of Molecular Therapeutics, Center for Food and Medical Innovation, Hokkaido University, Sapporo, Japan
| | - Akihiro Miyazaki
- Department of Oral Surgery, Sapporo Medical University, Sapporo, Japan
| | | | | | - Noriyuki Sato
- Department of Pathology, Sapporo Medical University, Sapporo, Japan
| |
Collapse
|
17
|
van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJM. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer 2016; 16:219-33. [PMID: 26965076 DOI: 10.1038/nrc.2016.16] [Citation(s) in RCA: 494] [Impact Index Per Article: 61.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Therapeutic vaccines preferentially stimulate T cells against tumour-specific epitopes that are created by DNA mutations or oncogenic viruses. In the setting of premalignant disease, carcinoma in situ or minimal residual disease, therapeutic vaccination can be clinically successful as monotherapy; however, in established cancers, therapeutic vaccines will require co-treatments to overcome immune evasion and to become fully effective. In this Review, we discuss the progress that has been made in overcoming immune evasion controlled by tumour cell-intrinsic factors and the tumour microenvironment. We summarize how therapeutic benefit can be maximized in patients with established cancers by improving vaccine design and by using vaccines to increase the effects of standard chemotherapies, to establish and/or maintain tumour-specific T cells that are re-energized by checkpoint blockade and other therapies, and to sustain the antitumour response of adoptively transferred T cells.
Collapse
Affiliation(s)
| | - Ramon Arens
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
| | - Ferry Ossendorp
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
| | | | - Cornelis J M Melief
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
- ISA Pharmaceuticals, J. H. Oortweg 19, 2333 CH, Leiden, The Netherlands
| |
Collapse
|
18
|
Bhattacharyya T, Purushothaman K, Puthiyottil SSV, Bhattacharjee A, Muttah G. Immunological interactions in radiotherapy-opening a new window of opportunity. ANNALS OF TRANSLATIONAL MEDICINE 2016; 4:51. [PMID: 26904573 DOI: 10.3978/j.issn.2305-5839.2015.10.44] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
After a span of significant developments & advances we have reached a plateau in all the oncological disciplines in last decade. Escalation of dose of radiotherapy (RT) became possible with emergence of intensity modulated radiotherapy (IMRT) and image guided radiotherapy (IGRT). Different radiosensitizing agents starting from conventional cytotoxic drugs to hypoxic radiosensitizers have been tried to increase the effect of RT. However technological advancement hasn't been translated into significant clinical benefits. Exploiting the immune system to enhance the effect of RT is a relatively new concept and a fast growing area in the field of oncology. RT cannot longer be considered as a localized treatment, but rather as a systemic weapon for solid tumors. The phenomenon of abscopal effect, meaning the action of RT upon distant 'out-of-field' foci of malignancies has been a major focus of recent research, and holds great promise for the future. In this review article we are going to discuss the immunological interactions in RT and its promising clinical implications.
Collapse
Affiliation(s)
- Tapesh Bhattacharyya
- 1 Department of Radiation Oncology, 2 Division of Clinical Research and Biostatistics, Malabar Cancer Centre, Thalassery, Kerala, India
| | - Kiran Purushothaman
- 1 Department of Radiation Oncology, 2 Division of Clinical Research and Biostatistics, Malabar Cancer Centre, Thalassery, Kerala, India
| | | | - Atanu Bhattacharjee
- 1 Department of Radiation Oncology, 2 Division of Clinical Research and Biostatistics, Malabar Cancer Centre, Thalassery, Kerala, India
| | - Geetha Muttah
- 1 Department of Radiation Oncology, 2 Division of Clinical Research and Biostatistics, Malabar Cancer Centre, Thalassery, Kerala, India
| |
Collapse
|
19
|
Abstract
PURPOSE OF REVIEW To review the recent developments in our understanding of endoplasmic reticulum (ER) aminopeptidase 1 (ERAP1) function in relation to its role in major histocompatibility complex (MHC) class I peptide presentation and human leukocyte antigen (HLA) class I-associated diseases. RECENT FINDINGS ERAP1 polymorphisms exhibiting loss-of-function have been associated with protection from AS. The aminopeptidase function of ERAP1 optimizes peptides for binding and presentation by MHC class I. Most of the studies have revealed reduced MHC class I expression in situations of reduced ERAP1 function. Under these circumstances, the presented peptides are often N-terminally extended, and cell surface complexes are unstable and fall apart more readily. In contrast, peptides presented by HLA-B*27 : 05 when ERAP1 is silenced are frequently extended on the C-terminus. Recent work has emphasized on the importance of assessing the function of allotypes encoded by ERAP1 haplotypes, rather than effects of single amino acid substitutions. The allotypes found in a series of AS patients were poorer at restoring HLA-B27 expression than allotypes found in unaffected controls, which may seem contrary to the genetic data linking loss-of-function to protection. SUMMARY More work is needed to understand how ERAP1 variants associated with risk and protection influence the quality and quantity of peptides available for binding to HLA class I molecules in the ER. Moreover, we need to determine allele-specific effects of ERAP1 variants in the context of HLA-B*51 and HLA-Cw*6, which are associated with Behçet's disease and psoriasis, respectively.
Collapse
|
20
|
Interaction of TAPBPR, a tapasin homolog, with MHC-I molecules promotes peptide editing. Proc Natl Acad Sci U S A 2016; 113:E1006-15. [PMID: 26869717 DOI: 10.1073/pnas.1519894113] [Citation(s) in RCA: 59] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Peptide loading of major histocompatibility complex class I (MHC-I) molecules is central to antigen presentation, self-tolerance, and CD8(+) T-cell activation. TAP binding protein, related (TAPBPR), a widely expressed tapasin homolog, is not part of the classical MHC-I peptide-loading complex (PLC). Using recombinant MHC-I molecules, we show that TAPBPR binds HLA-A*02:01 and several other MHC-I molecules that are either peptide-free or loaded with low-affinity peptides. Fluorescence polarization experiments establish that TAPBPR augments peptide binding by MHC-I. The TAPBPR/MHC-I interaction is reversed by specific peptides, related to their affinity. Mutational and small-angle X-ray scattering (SAXS) studies confirm the structural similarities of TAPBPR with tapasin. These results support a role of TAPBPR in stabilizing peptide-receptive conformation(s) of MHC-I, permitting peptide editing.
Collapse
|
21
|
Immunogenicity of infectious pathogens and vaccine antigens. BMC Immunol 2015; 16:31. [PMID: 26021448 PMCID: PMC4446803 DOI: 10.1186/s12865-015-0095-y] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2014] [Accepted: 02/20/2015] [Indexed: 12/28/2022] Open
Abstract
The concept of the immunogenicity of an antigen is frequently encountered in the context of vaccine development, an area of intense interest currently due to the emergence or re-emergence of infectious pathogens with the potential for worldwide spread. However, the theoretical notion of immunogenicity as discussed in older textbooks of immunology needs reconsideration due to advances in our understanding of immunologic responses. Immunogenicity is a property that can either be a desirable attribute, for example in the generation of an effective protective immunity against infectious pathogens or an undesirable trait, for example when it relates to novel therapeutic compounds and drugs, where an immune response needs to be prevented or inhibited. In this Forum Article, we aimed to revisit the issue of immunogenicity to discuss a series of simple questions relevant to the concept that are frequently rephrased but incompletely resolved in the immunologic literature.
Collapse
|